You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
李氏大药厂(00950.HK)荣获科睿唯安颁赠“2019年亚太地区最具创新力中小型制药企业奖”
格隆汇 09-06 19:34

格隆汇9月6日丨李氏大药厂(00950.HK)发布公告,2019年8月29日,公司荣获科睿唯安(一间数码健康智能解决方案供应商)品评为“2019年亚太地区最具创新力中小型制药企业奖”排名榜的第一位。集团相信,这奖项标志着集团在研发新药以应对医疗需求缺口方面的创新领先地位及承诺皆获得认可。

获得“2019年亚太地区最具创新力中小型制药企业奖”此殊荣的公司乃根据多项准则予以评,包括(但不限于)开发中产品资产及已推出产品的数目。集团将继续维持开发创新药品,以扩阔集团增长机会,为投资者带来理想回报。

根据科睿唯安,此乃首次专注于亚太地区的分析,采用专门针对制药行业及成熟程度较低的市场而设计的方法。与其他创新研究不同,此处提出的亚太地区结果并未被全球规模的调查结果所掩盖,也没有对该地区创新力计量进行更改。该分析是根据2019年第一季度所收集数据进行的,并将研究限于医药及生物制药产品,而药物输送、设备及诊断方面的辅助创新力则视为超出研究范围。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account